AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
trometamol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2771 | 77-86-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -4.611 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.296 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.414 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 0.628 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 98.480 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 98.730 | % | High | 1 |
| herg | hERG pIC50 | 4.421 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.130 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 2.938 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 98.310 | % | High | 1 |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.309 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 0.499 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 99.250 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.385 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 98.160 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 0.982 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 97.270 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 99.250 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 1132.400 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 16, 1965 | FDA | HOSPIRA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B05BB03 | BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTIONS Solutions affecting the electrolyte balance |
| ATC | B05XX02 | BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Other i.v. solution additives |
| MeSH PA | D002021 | Buffers |
| MeSH PA | D005079 | Excipients |
| MeSH PA | D010592 | Pharmaceutic Aids |
| MeSH PA | D014677 | Pharmaceutical Vehicles |
| CHEBI has role | CHEBI:35225 | buffer compounds |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
| Post-Op Photophobia | indication | ||
| Postoperative Ocular Pain | indication | ||
| Post-Op Ocular Inflammation | indication | ||
| Anuria | contraindication | 2472002 | DOID:2983 |
| Respiratory acidosis | contraindication | 12326000 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Hyperkalemia | contraindication | 14140009 | |
| Disorder of cornea | contraindication | 15250008 | DOID:10124 |
| Acute gastric ulcer with perforation | contraindication | 19850005 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
| Hypovolemia | contraindication | 28560003 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Uremia | contraindication | 44730006 | DOID:4676 |
| Tear film insufficiency | contraindication | 46152009 | |
| Chronic heart failure | contraindication | 48447003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Corneal erosion | contraindication | 50792001 | |
| Duodenal ulcer disease | contraindication | 51868009 | DOID:1724 |
| Acute nephropathy | contraindication | 58574008 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Rheumatoid arthritis | contraindication | 69896004 | DOID:7148 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Decreased respiratory function | contraindication | 80954004 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Hemophilia | contraindication | 90935002 | |
| Corneal degeneration | contraindication | 111521006 | DOID:1237 |
| Perioperative care | contraindication | 133897009 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Impaired renal function disorder | contraindication | 197663003 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Coronary artery bypass graft | contraindication | 232717009 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Hypoglycemic disorder | contraindication | 237630007 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Cerebral hemorrhage | contraindication | 274100004 | |
| Pregnancy, function | contraindication | 289908002 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Smokes tobacco daily | contraindication | 449868002 | |
| Salicylate Intoxication | contraindication | ||
| Preoperative Pain Management | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.07 | acidic |
| pKa2 | 13.54 | acidic |
| pKa3 | 8.25 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018096 | VUID |
| N0000146434 | NUI |
| D00396 | KEGG_DRUG |
| 4018096 | VANDF |
| C0041175 | UMLSCUI |
| CHEBI:9754 | CHEBI |
| CHEMBL1200391 | ChEMBL_ID |
| DB03754 | DRUGBANK_ID |
| 6503 | PUBCHEM_CID |
| 10865 | RXNORM |
| 5644 | MMSL |
| 80879 | MMSL |
| d00472 | MMSL |
| 000751 | NDDF |
| 404882002 | SNOMEDCT_US |
| 59034000 | SNOMEDCT_US |
| D014325 | MESH_DESCRIPTOR_UI |
| TMN | PDB_CHEM_ID |
| TRS | PDB_CHEM_ID |
| 1108 | INN_ID |
| 7328 | IUPHAR_LIGAND_ID |
| 023C2WHX2V | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TROMETHAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0264-8031 | INJECTION, SOLUTION | 3.60 g | INTRAVENOUS | ANDA | 17 sections |
| THAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1593 | INJECTION, SOLUTION | 3.60 g | INTRAVENOUS | NDA | 17 sections |
| SOORYEHAN HYO FERMENTED SUN BLOCK | HUMAN OTC DRUG LABEL | 7 | 53208-549 | CREAM | 2.63 mL | TOPICAL | OTC monograph not final | 7 sections |
| Tromethamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71357-001 | INJECTION, SOLUTION | 3.60 g | INTRAVENOUS | ANDA | 11 sections |
| AnubisMed | HUMAN OTC DRUG LABEL | 28 | 83021-551 | CREAM | 0.22 g | TOPICAL | OTC monograph final | 7 sections |
| Anubis Barcelona Protective Line | HUMAN OTC DRUG LABEL | 27 | 83021-686 | CREAM | 0.22 g | TOPICAL | OTC monograph final | 9 sections |